期刊文献+

调脂降糖片治疗痰瘀互结型代谢综合征临床研究 被引量:4

Clinical study on effect of "Tiaozhi Jiangtang Tablet" in treating metabolic syndrome of intermingled phlegm and blood stasis
原文传递
导出
摘要 目的观察调脂降糖片治疗痰瘀互结型代谢综合征的临床疗效。方法将60例痰瘀互结型代谢综合征患者随机分为两组,每组30例,除接受基础治疗外,治疗组予调脂降糖片、对照组予二甲双胍缓释片(泰白),疗程均为3个月。观察每组治疗前后空腹血糖(FPG)、糖化血红蛋白(HbA1c)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-c)、收缩压(SBP)、舒张压(DBP)、腰围(WC)、体质量指数(BMI)、中医证候的变化。结果治疗组HDL-c升高,TG、WC、中医证候积分降低,较对照组差异有统计学意义(P<0.01,P<0.05);两组降糖疗效差异无统计学意义(P>0.05)。结论调脂降糖片能显著改善痰瘀互结型代谢综合征患者脂代谢、糖代谢,降低体质量,并能改善中医证候。 Objective To observe clinical effect of "Tiaozhi Jiangtang Tablet" in treating metabolic syndrome of intermingled phlegm and blood stasis.Methods Sixty subjects were randomly divided into treatment group and control group,30 cases in each group.The patients in the treatment group were treated with "Tiaozhi Jiangtang Tablet",and those in the control group received extended action tablet of metformin,with a course of three months.The levels of FPG,HbA1c,TG,HDL-c,SBP,DBP,WC,BMI and clinical symptom were observed.Results Compared with the control group,the levels of HDL-c increased;TG,WC and clinical symptom scores decreased in the treatment group(P〈0.05,P〈0.01),but the effect on FPG and HbA1c had no significant difference between the two groups(P〈0.05).Conclusion "Tiaozhi Jiangtang Tablet" can improve lipid and glucose metablism,and clinical symptoms of metabolic syndrome of intermingled phlegm and blood stasis.
出处 《上海中医药杂志》 2010年第10期30-32,共3页 Shanghai Journal of Traditional Chinese Medicine
关键词 代谢综合征 痰瘀互结 调脂降糖片 临床研究 Metabolic syndrome intermingled phlegm and blood stasis "Tiaozhi Jiangtang Tablet" clinical study
  • 相关文献

参考文献6

二级参考文献31

  • 1李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2126
  • 2Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med,2003,4(suppl 6):s11-s18.
  • 3Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol,1994,73:460-468.
  • 4Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med,2003,115(suppl 8A):24s-28s.
  • 5Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care,2003,26:1513-1517.
  • 6Steinmetz A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes,2001,109:s548-559.
  • 7Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA, 2001,285:1585-1591.
  • 8Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care, 2004,27:1182-1186.
  • 9Lindstrom J, Louheranta A, Mannelin M. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care, 2003,26:3230-3236.
  • 10Tuomilehto J, Lindstrm J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. NEJM, 2001,344:1343-1350.

共引文献672

同被引文献61

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部